Dr. Philip Bonomi, MD

Name: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Start: 2025-09-07T18:30:00+02:00
End: 2025-09-07T19:30:00+02:00

November 1, 2016

|

By

|

Estimated Read Time:

1 minute

Names & News

Dr. Philip Bonomi completed his service as Director of the Division of Hematology, Oncology and Cell Therapy at Rush University Medical Center, Chicago, US, a position he has held since 2002. Professor Bonomi is the Alice Pirie Wirtz Professor of Medical Oncology at Rush, where he continues his work as a lung cancer researcher and clinician.

About the Authors

Share this Article:

Dr. Philip Bonomi, MD

Recent Posts

World Conference Conversations: Inside WCLC 2025

Opening Plenary to Highlight Significant Achievements in Thoracic Oncology

Third Annual Amazing Case Race Returns for WCLC 2025

Preconference Workshops Offer Diverse Educational Opportunities Across Specialties

IS03: Satellite EBAC/CME Symposium by Answers in CME: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC